Shigemichi Iwae1, Masato Fujii2, Ryuichi Hayashi3, Yasuhisa Hasegawa4, Takashi Fujii5, Kenji Okami6, Akihiro Homma7, Tetsuro Onitsuka8, Takakuni Kato9, Takenori Ogawa10, Kyoichi Terao11, Nobuya Monden12, Naoki Otsuki13, Hiroshi Nishino14, Ichiro Ota15, Yasushi Fujimoto16, Kazuto Matsuura17, Kazuyoshi Kawabata18, Hidetoshi Matsui19, Koichiro Yonezawa19, Ken-Ichi Nibu13. 1. Department of Head and Neck Surgery, Hyogo Cancer Center, 13-70 Kitaoji, Akashi, Hyogo, 673-8558, Japan. s.iwae@hp.pref.hyogo.jp. 2. Department of Otolaryngology, Eiju General Hospital, Tokyo, Japan. 3. Division of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. 4. Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan. 5. Department of Head and Neck Surgery, Osaka International Cancer Institute, Osaka, Japan. 6. Department of Otolaryngology, Tokai University, Isehara, Kanagawa, Japan. 7. Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. 8. Department of Head and Neck Surgery, Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan. 9. Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, Japan. 10. Department of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. 11. Department of Otolaryngology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan. 12. Department of Head and Neck surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan. 13. Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan. 14. Department of Otolaryngology and Head and Neck Surgery, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan. 15. Department of Otolaryngology-Head and Neck Surgery, Nara Medical University, Kashihara, Nara, Japan. 16. Department of Otolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 17. Division of Head and Neck Surgery, Miyagi Cancer Center, Natori, Miyagi, Japan. 18. Department of Head and Neck Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 19. Department of Head and Neck Surgery, Hyogo Cancer Center, 13-70 Kitaoji, Akashi, Hyogo, 673-8558, Japan.
Abstract
BACKGROUND: The aim of this study was to compare the therapeutic outcomes of total pharyngolaryngectomy with those of concomitant chemoradiotherapy in advanced hypopharyngeal cancer. METHODS: This is a retrospective multi-institutional study. The medical records of 979 patients with hypopharyngeal cancer, who were initially treated between 2006 and 2008, were reviewed. In this study, we matched a group of total pharyngolaryngectomy patients with a second group of chemoradiotherapy patients, according to age, gender, subsite, arytenoid fixation, cartilage invasion, and N classification, and analyzed overall survival, disease-specific survival, and locoregional control rates. RESULTS: The matched-pair analysis included 254 patients. The 5-year overall survival, disease-specific survival, and locoregional control rates were 58.5% and 53.5% (P = 0.30), 68.9% and 68.0% (P = 0.80), and 82.2% and 63.6% (P < 0.01), respectively, for patients in the total pharyngolaryngectomy and chemoradiotherapy groups. For T4a patients with cartilage invasion, the matched-pair analysis included 46 patients. The 5-year overall survival, disease-specific, and locoregional control rates were 56.5% and 26.0% (P = 0.092), 56.5% and 41.3% (P = 0.629), and 43.0% and 42.5% (P = 0.779), respectively, for patients in the total pharyngolaryngectomy and chemoradiotherapy groups. CONCLUSIONS: The data from this large-scale multi-institutional joint research program of hypopharyngeal cancer in Japan suggest that chemoradiotherapy may provide adequate survival benefit for hypopharyngeal cancer patients with the distinct advantage of larynx preservation. Our data also suggest that chemoradiotherapy is as beneficial as total pharyngolaryngectomy for the local control of locally advanced hypopharyngeal cancer.
BACKGROUND: The aim of this study was to compare the therapeutic outcomes of total pharyngolaryngectomy with those of concomitant chemoradiotherapy in advanced hypopharyngeal cancer. METHODS: This is a retrospective multi-institutional study. The medical records of 979 patients with hypopharyngeal cancer, who were initially treated between 2006 and 2008, were reviewed. In this study, we matched a group of total pharyngolaryngectomy patients with a second group of chemoradiotherapy patients, according to age, gender, subsite, arytenoid fixation, cartilage invasion, and N classification, and analyzed overall survival, disease-specific survival, and locoregional control rates. RESULTS: The matched-pair analysis included 254 patients. The 5-year overall survival, disease-specific survival, and locoregional control rates were 58.5% and 53.5% (P = 0.30), 68.9% and 68.0% (P = 0.80), and 82.2% and 63.6% (P < 0.01), respectively, for patients in the total pharyngolaryngectomy and chemoradiotherapy groups. For T4a patients with cartilage invasion, the matched-pair analysis included 46 patients. The 5-year overall survival, disease-specific, and locoregional control rates were 56.5% and 26.0% (P = 0.092), 56.5% and 41.3% (P = 0.629), and 43.0% and 42.5% (P = 0.779), respectively, for patients in the total pharyngolaryngectomy and chemoradiotherapy groups. CONCLUSIONS: The data from this large-scale multi-institutional joint research program of hypopharyngeal cancer in Japan suggest that chemoradiotherapy may provide adequate survival benefit for hypopharyngeal cancerpatients with the distinct advantage of larynx preservation. Our data also suggest that chemoradiotherapy is as beneficial as total pharyngolaryngectomy for the local control of locally advanced hypopharyngeal cancer.
Authors: J L Lefebvre; D Chevalier; B Luboinski; A Kirkpatrick; L Collette; T Sahmoud Journal: J Natl Cancer Inst Date: 1996-07-03 Impact factor: 13.506
Authors: Jun Won Kim; Mi Sun Kim; Se-Heon Kim; Joo Hang Kim; Chang Geol Lee; Gwi Eon Kim; Ki Chang Keum Journal: Cancer Res Treat Date: 2015-03-13 Impact factor: 4.679